Vaccination Analysis in China
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 1764
Special Issue Editors
Interests: infectious and chronic disease prevention and control
Special Issue Information
Dear Colleagues,
As you are already aware, infectious diseases have been an important factor in population health. In the field of infectious disease prevention and control, no medical strategy has surpassed vaccination in reducing morbidity and mortality. Vaccination is one of the most cost-effective health investments, and is a proven means to control and eliminate infectious diseases, and is estimated to avoid 2 million to 3 million deaths per year. In many developed countries, infectious disease deaths account for only 4% to 8% of the total deaths, mainly due to the widespread use of vaccines. In some developing countries, 30 or even 50 percent of the total deaths still die from infectious diseases.
At present, COVID-19, hepatitis B, influenza, pneumonia and HPV are the infectious diseases of great concern in China. The COVID-19 pandemic has caused immeasurable losses across the country and around the world, however, the latest Lancet data in 2019, including China (India, Nigeria, Indonesia, Pakistan, China) accounted for 54% of the total global cases, and the burden of Spn pneumonia for children under 5 in China. As we all know, China has the highest burden of HBV infection in the world. Meanwhile, cervical cancer is the second largest female malignancy after ovarian cancer. In order to control these most important infectious diseases, the only way to prevent infection is to develop effective vaccines, and vaccination is also the most economical and efficient method.
However, right now, only nine vaccines in China have passed the WHO vaccine pre-certification, which is not commensurate with China's national strength and the actual regulatory level. Moreover, in the actual HPV vaccination, the vaccination rate of HPV vaccine among Chinese adolescent women is still relatively low. Influenza vaccines are not included in China's national immunization program, which have gradually increased over the past 15 years, but have only covered about 2 percent of the population. What are the causes of these phenomena, how to deal with these situations, how to refine the evaluation criteria of vaccine efficacy, still need to be further explored.
To achieve a broader understanding of the current trends in vaccination and the latest scientific research, this journal is published. Based on your extensive knowledge and experience, we invite you to write original reports, original observations, or reviews to highlight (i) the latest research progress in vaccination, (ii) the status and challenges of vaccines in China, and (iii) the future and development of vaccines in China.
Dr. Xiaofeng Liang
Dr. Dan Liu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccinations
- vaccines
- COVID-19
- Hepatitis B
- influenza
- Pneumonia
- Human Papillomavirus (HPV)
